| Literature DB >> 31875016 |
Nunzia Passaro1, Andrea Casagrande2, Matteo Chiara3, Bruno Fosso4, Caterina Manzari4, Anna Maria D'Erchia4,5, Samuele Iesari6,7, Francesco Pisani6, Antonio Famulari6, Patrizia Tulissi8, Stefania Mastrosimone9, Maria Cristina Maresca9, Giuseppe Mercante10,11, Giuseppe Spriano10,11, Giacomo Corrado12,13, Enrico Vizza12, Anna Rosa Garbuglia14, Maria Rosaria Capobianchi14, Carla Mottini1, Alessandra Cenci2, Marco Tartaglia15, Alessandro Nanni Costa16, Graziano Pesole4,5, Marco Crescenzi17.
Abstract
The possible existence of yet undiscovered human tumorigenic viruses is still under scrutiny. The development of large-scale sequencing technologies, coupled with bioinformatics techniques for the characterization of metagenomic sequences, have provided an invaluable tool for the detection of unknown, infectious, tumorigenic agents, as demonstrated by several recent studies. However, discoveries of novel viruses possibly associated with tumorigenesis are scarce at best. Here, we apply a rigorous bioinformatics workflow to investigate in depth tumor metagenomes from a small but carefully selected cohort of immunosuppressed patients. While a variegated bacterial microbiome was associated with each tumor, no evidence of the presence of putative oncoviruses was found. These results are consistent with the major findings of several recent papers and suggest that new human tumorigenic viruses are not common even in immunosuppressed populations.Entities:
Mesh:
Year: 2019 PMID: 31875016 PMCID: PMC6930283 DOI: 10.1038/s41598-019-56240-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Tumors analyzed.
| Code | Tumor type | Nucleic acid sequenced | Immunosuppressive condition (IC) | Years from onset of IC |
|---|---|---|---|---|
| T1 | Skin squamous cell carcinoma | RNA | Renal transplantation, immunosuppressive therapy | 20 |
| T2 | Skin basal cell carcinoma | RNA | Renal transplantation, immunosuppressive therapy | 9 |
| T5 | Native kidney (oncocytoma) | RNA | Renal transplantation, immunosuppressive therapy | 19 |
| T7 | Transplanted kidney (clear cell carcinoma) | DNA and RNA | Renal transplantation, immunosuppressive therapy | 3 |
| T8 | Native kidney (oncocytoma) | DNA | Renal transplantation, immunosuppressive therapy | 20 |
| T9 | Non-Hodgkin Lymphoma | DNA | Renal transplantation, immunosuppressive therapy | 12 |
| T10 | Colon adenocarcinoma | DNA | Renal transplantation, immunosuppressive therapy | 5 |
| T11 | Native kidney (clear cell carcinoma) | RNA | Renal transplantation, immunosuppressive therapy | 7 |
| T12, T13 | Two skin carcinomas | RNA | Renal transplantation, immunosuppressive therapy | 12 |
| T14 | Skin squamous cell carcinoma | RNA | Renal transplantation, immunosuppressive therapy | 8 |
| N4 | Carcinoma of the tongue and oropharynx | RNA | Non-Hodgkin lymphoma | 15 |
| N6 | Lip squamous cell carcinoma (HPV-neg.) | RNA | Acute lymphocytic leukemia | 11 |
Metagenomics analyses.
| Code | Nucleic acid sequenced | Denoised PE reads analyzeda | Human-like scaffoldsb | Notable findings |
|---|---|---|---|---|
| T1 | RNA | 109,426,939 | 98 | Coxsackievirus (1 scaffold) |
| T2 | RNA | 100,344,056 | 43 | |
| T5 | RNA | 80,678,185 | 43 | |
| T7 DNA | DNA | 101,083,848 | 664 | |
| T7 RNA | RNA | 90,253,628 | 1058 | |
| T8 | DNA | 136,198,410 | 254 | TTV (3 scaffolds) |
| T9 | DNA | 95,189,284 | 518 | |
| T10 | DNA | 58,588,892 | 1246 | |
| T11 | RNA | 105,289,212 | 1046 | |
| T12 | RNA | 117,697,380 | 89 | |
| T13 | RNA | 96,539,124 | 265 | |
| N3 | RNA | 85,965,850 | 67 | |
| N4 | RNA | 80,826,768 | 32 | |
| N6 | RNA | 95,336,818 | 69 | TTV (1 scaffold) |
aActual number of reads analyzed, after removing low-quality ones. bScaffolds are constructed by linking together a non-contiguous series of genomic sequences, consisting of sequences separated by gaps of known length; linked sequences are typically contiguous, corresponding to read overlaps.
Figure 1Schematic of the sequence analysis workflow.
Probability to detect the presence of viruses.
| % prevalence | % detection probability1 | ||
|---|---|---|---|
| n = 4 | n = 5 | n = 13 | |
| 10 | 34.39 | 40.95 | 74.58 |
| 20 | 59.04 | 67.23 | 94.50 |
| 30 | 75.99 | 83.19 | 99.03 |
| 50 | 93.75 | 96.88 | 99.99 |
| 80 | 99.84 | 99.97 | >99.99 |
1Probability to observe a virus that has the indicated hypothetical prevalence in the tumor group considered, in at least one of n samples. Probability is calculated according to the following formula: D = [1 − (1 − P)n] × 100, where D is detection probability and P is prevalence, with 0 ≤ P ≤ 1.